{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:22:50Z","timestamp":1778494970145,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and aims<\/jats:title>\n            <jats:p>Liver cancer is the third leading cause of cancer related death due to treatment resistance and late onset of symptoms (Rumgay in J Hepatol 77: 1598\u20131606, 2022). The role of external beam radiotherapy (EBRT) in treatment of unresectable liver cancer needs to be defined. The use of particle therapy such as carbon ion radiation therapy (CIRT) with high linear energy transfer (LET) could increase efficacy of EBRT while limiting the toxic effects of radiation on non-cancerous liver tissue. Promising effects of CIRT have been described in several studies during the past decades, mostly in Japan. To date, no standardized treatment protocol has been established and European data on CIRT for liver cancer is lacking. This retrospective analysis aims to investigate efficacy and safety of hypofractionated CIRT compared to photon-based stereotactic body radiation (SBRT) in primary liver cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>Thirty-six (n\u2009=\u200936) and twenty (n\u2009=\u200920) patients with primary malignant liver tumors were treated with hypofractionated CIRT (4 fractions) and photon-based SBRT, respectively, between 2011 and 2022 and were retrospectively evaluated for survival, local control, and toxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Two-year local control rate after CIRT was 92.3%. Compared to photon- based SBRT, CIRT scores with a significantly longer median distant progression free survival (3.1 versus 0.9\u00a0years). In a matched pair comparison of the two treatment regimens, the CIRT cohort demonstrated both longer 2-year overall survival (100% versus 59.6%) and longer 2-year distant PFS (75.7% versus 22.9%). No significant impairment of liver function was observed in either cohort.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In this retrospective analysis, patients who received CIRT presented excellent local tumor control and had better oncologic outcomes than patients who received photon-based SBRT. SBRT with carbon ions is a promising local ablative treatment option that needs further investigation in large prospective trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13014-025-02594-y","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T05:08:34Z","timestamp":1739855314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Stereotactic body radiotherapy with carbon ions as local ablative treatment in patients with primary liver cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Paula","family":"Hoffmeister-Wittmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Hoegen-Sa\u00dfmannshausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Wicklein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Weykamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Seidensaal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Springfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T.","family":"Dill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Longerich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schirmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianeb","family":"Mehrabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9 Michael","family":"Mathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno C.","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Herfarth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Liermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"2594_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA, Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598\u2013606. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021.","journal-title":"J Hepatol"},{"key":"2594_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.32074\/1591-951X-295","volume":"113","author":"SL Renne","year":"2021","unstructured":"Renne SL, Sarcognato S, Sacchi D, Guido M, Roncalli M, Terracciano L, Di Tommaso L. Hepatocellular carcinoma: a clinical and pathological overview. Pathologica. 2021;113:203\u201317. https:\/\/doi.org\/10.32074\/1591-951X-295.","journal-title":"Pathologica"},{"key":"2594_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589\u2013604. https:\/\/doi.org\/10.1038\/s41575-019-0186-y.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2594_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"key":"2594_CR5","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.4254\/wjh.v7.i18.2147","volume":"7","author":"WH She","year":"2015","unstructured":"She WH, Chok K. Strategies to increase the resectability of hepatocellular carcinoma. World J Hepatol. 2015;7:2147\u201354. https:\/\/doi.org\/10.4254\/wjh.v7.i18.2147.","journal-title":"World J Hepatol"},{"key":"2594_CR6","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1007\/s10620-007-9750-3","volume":"52","author":"OF Couto","year":"2007","unstructured":"Couto OF, Dvorchik I, Carr BI. Causes of death in patients with unresectable hepatocellular carcinoma. Dig Dis Sci. 2007;52:3285\u20139. https:\/\/doi.org\/10.1007\/s10620-007-9750-3.","journal-title":"Dig Dis Sci"},{"key":"2594_CR7","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.3748\/wjg.v25.i32.4614","volume":"25","author":"R Inchingolo","year":"2019","unstructured":"Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: current evidence and future directions. World J Gastroenterol. 2019;25:4614\u201328. https:\/\/doi.org\/10.3748\/wjg.v25.i32.4614.","journal-title":"World J Gastroenterol"},{"key":"2594_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJ, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2594_CR9","doi-asserted-by":"publisher","first-page":"100983","DOI":"10.1016\/j.jhepr.2023.100983","volume":"6","author":"D Tataru","year":"2024","unstructured":"Tataru D, Khan SA, Hill R, Morement H, Wong K, Paley L, Toledano MB. Cholangiocarcinoma across England: temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation. JHEP Rep. 2024;6:100983. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100983.","journal-title":"JHEP Rep"},{"key":"2594_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","volume":"72","author":"O Clements","year":"2020","unstructured":"Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020;72:95\u2013103. https:\/\/doi.org\/10.1016\/j.jhep.2019.09.007.","journal-title":"J Hepatol"},{"key":"2594_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102258","volume":"99","author":"J Edeline","year":"2021","unstructured":"Edeline J, et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. Cancer Treat Rev. 2021;99: 102258. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102258.","journal-title":"Cancer Treat Rev"},{"key":"2594_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/hep.29789","volume":"68","author":"E Brunt","year":"2018","unstructured":"Brunt E, et al. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology. 2018;68:113\u201326. https:\/\/doi.org\/10.1002\/hep.29789.","journal-title":"Hepatology"},{"key":"2594_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.cld.2020.07.006","volume":"24","author":"CP Chen","year":"2020","unstructured":"Chen CP. Role of external beam radiotherapy in hepatocellular carcinoma. Clin Liver Dis. 2020;24:701\u201317. https:\/\/doi.org\/10.1016\/j.cld.2020.07.006.","journal-title":"Clin Liver Dis"},{"key":"2594_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100498","volume":"4","author":"S Lewis","year":"2022","unstructured":"Lewis S, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity. JHEP Rep. 2022;4: 100498. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100498.","journal-title":"JHEP Rep"},{"key":"2594_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.semradonc.2005.04.005","volume":"15","author":"LA Dawson","year":"2005","unstructured":"Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol. 2005;15:279\u201383. https:\/\/doi.org\/10.1016\/j.semradonc.2005.04.005.","journal-title":"Semin Radiat Oncol"},{"key":"2594_CR16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2147\/JHC.S292516","volume":"8","author":"B Abousaida","year":"2021","unstructured":"Abousaida B, et al. Carbon ion radiotherapy in the management of hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1169\u201379. https:\/\/doi.org\/10.2147\/JHC.S292516.","journal-title":"J Hepatocell Carcinoma"},{"key":"2594_CR17","doi-asserted-by":"publisher","unstructured":"Hoegen-Sa\u00dfmannshausen, P. N., Patrick; Hoffmeister-Wittmann, Paula; Harrabi Semi Ben; Seidensaal, Katharina; Weykamp, Fabian; Mielke, Thomas; Ellerbrock, Malte; Habermehl, Daniel; Springfeld, Christoph; Dill, Michael T.; Longerich, Thomas; Schirmacher, Thomas; Mehrabi, Arianeb; Chang, De-Hua; H\u00f6rner-Rieber, Juliane; J\u00e4kel, Oliver; Haberer, Thomas; Combs, Stephanie E., Debus, J\u00fcrgen; Herfarth, Klaus; Liermann, Jakob. Carbon ion radiotherapy of hepatocellular carcinoma provides excellent local control: the prospective phase I PRROMETHEUS trial. JHEP Rep. 2024. https:\/\/doi.org\/10.1016\/j.hepr.2024.101063","DOI":"10.1016\/j.hepr.2024.101063"},{"key":"2594_CR18","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.18632\/oncotarget.27028","volume":"10","author":"G Kasuya","year":"2019","unstructured":"Kasuya G, et al. Carbon-ion radiotherapy for cholangiocarcinoma: a multi-institutional study by and the Japan carbon-ion radiation oncology study group (J-CROS). Oncotarget. 2019;10:4369\u201379. https:\/\/doi.org\/10.18632\/oncotarget.27028.","journal-title":"Oncotarget"},{"key":"2594_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108\u201318. https:\/\/doi.org\/10.1016\/j.ejca.2021.11.023.","journal-title":"Eur J Cancer"},{"key":"2594_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000520277","volume":"11","author":"K Shibuya","year":"2022","unstructured":"Shibuya K, et al. Efficacy and safety of 4 fractions of carbon-ion radiation therapy for hepatocellular carcinoma: a prospective study. Liver Cancer. 2022;11:61\u201374. https:\/\/doi.org\/10.1159\/000520277.","journal-title":"Liver Cancer"},{"key":"2594_CR21","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.ijrobp.2004.01.032","volume":"59","author":"H Kato","year":"2004","unstructured":"Kato H, et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys. 2004;59:1468\u201376. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.01.032.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2594_CR22","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1002\/cncr.30816","volume":"123","author":"G Kasuya","year":"2017","unstructured":"Kasuya G, et al. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: combined analyses of 2 prospective trials. Cancer. 2017;123:3955\u201365. https:\/\/doi.org\/10.1002\/cncr.30816.","journal-title":"Cancer"},{"key":"2594_CR23","doi-asserted-by":"publisher","first-page":"21517","DOI":"10.1038\/s41598-020-78577-8","volume":"10","author":"L Hartmann","year":"2020","unstructured":"Hartmann L, et al. Photon versus carbon ion irradiation: immunomodulatory effects exerted on murine tumor cell lines. Sci Rep. 2020;10:21517. https:\/\/doi.org\/10.1038\/s41598-020-78577-8.","journal-title":"Sci Rep"},{"key":"2594_CR24","doi-asserted-by":"publisher","first-page":"01TR02","DOI":"10.1088\/1361-6560\/aa9102","volume":"63","author":"CP Karger","year":"2017","unstructured":"Karger CP, Peschke P. RBE and related modeling in carbon-ion therapy. Phys Med Biol. 2017;63:01TR02. https:\/\/doi.org\/10.1088\/1361-6560\/aa9102.","journal-title":"Phys Med Biol"},{"key":"2594_CR25","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.ijrobp.2012.01.038","volume":"84","author":"O Steinstrater","year":"2012","unstructured":"Steinstrater O, et al. Mapping of RBE-weighted doses between HIMAC- and LEM-based treatment planning systems for carbon ion therapy. Int J Radiat Oncol Biol Phys. 2012;84:854\u201360. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.01.038.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2594_CR26","doi-asserted-by":"publisher","unstructured":"Vogel A, Martinelli E, clinicalguidelines@esmo.org, EGCE a & Committee, EG. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 32, 801\u2013805, https:\/\/doi.org\/10.1016\/j.annonc.2021.02.014 (2021).","DOI":"10.1016\/j.annonc.2021.02.014"},{"key":"2594_CR27","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/annonc\/mdy510","volume":"30","author":"A Vogel","year":"2019","unstructured":"Vogel A, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:871\u20133. https:\/\/doi.org\/10.1093\/annonc\/mdy510.","journal-title":"Ann Oncol"},{"key":"2594_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ijrobp.2023.03.064","volume":"117","author":"AM Romero","year":"2023","unstructured":"Romero AM, van der Holt B, Willemssen FE, de Man RA, Heijmen BJ, Habraken S, Westerveld H, van Delden OM, Kl\u00fcmpen HJ, Tjwa ET, Braam PM. Transarterial chemoembolization with drug-eluting beads vs stereotactic body radiation therapy for hepatocellular carcinoma: Outcomes from a multicenter randomized phase II trial (The TRENDY trial): short running title: TACE-DEB versus SBRT for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2023;117:45. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.03.064.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2594_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13014-019-1347-4","volume":"14","author":"S Shiba","year":"2019","unstructured":"Shiba S, et al. A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study. Radiat Oncol. 2019;14:137. https:\/\/doi.org\/10.1186\/s13014-019-1347-4.","journal-title":"Radiat Oncol"},{"key":"2594_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","volume":"12","author":"S Apisarnthanarax","year":"2022","unstructured":"Apisarnthanarax S, et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2022;12:28\u201351. https:\/\/doi.org\/10.1016\/j.prro.2021.09.004.","journal-title":"Pract Radiat Oncol"},{"key":"2594_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.prro.2023.08.016","volume":"14","author":"TK Yanagihara","year":"2024","unstructured":"Yanagihara TK, et al. Defining minimum treatment parameters of ablative radiation therapy in patients with hepatocellular carcinoma: an expert consensus. Pract Radiat Oncol. 2024;14:134\u201345. https:\/\/doi.org\/10.1016\/j.prro.2023.08.016.","journal-title":"Pract Radiat Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02594-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02594-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02594-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T05:08:36Z","timestamp":1739855316000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02594-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2594"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02594-y","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P.H.W. was supported by the NCT Heidelberg School of Oncology Fellowship Program. P.H.S. was supported by the Physician Scientist Program of the Medical Faculty from 2021 to 2024, has a grant from Dietmar-Hopp Foundation and is part of NovoCure GmbH Advisory Board outside the submitted work. F.W. received speaker fees from AstraZeneca, Varian Medical Systems and Merck Sharp & Dohme and travel Support for attending meetings from Varian Medical Systems and Micropos Medical. M.T.D. received funding from German Cancer Aid, Uniscientia Foundation and Schwiete Foundation, got paid honoraria by Roche and Thieme and received funding for meeting fees by AstraZeneca and is part of AstraZeneca and Eisai Advisory Board outside of this work. B.C.K. received funding from German Cancer Aid, had contracts with AbbVie, Roche and Gilead, received consulting fees from Takeda and speaking honoraria as well as travel compensation from Servier and Pierre Fabre. J.D. received grants from CRI \u2013 The Clinical Research Institue GmbH, View Ray Inc., Accuray International S\u00e0rl, Accuray Incorporated, RaySearch Laboratories AB, Vision RT limited, Merck Serono GmbH, Astellas Pharma GmbH, Astra Zeneca GmbH, Solution Akademie GmbH, Ergomed PLC Surrey Research Park, Siemens Healthcare GmbH, Quintiles GmbH, Pharmaceutecal Research Associates GmbH, Boehringer Ingelheim Pharma GmbH Co, PTW- Freiburg Dr. Pychlau GmbH, Nanobiotix A.A. outside the submitted work. J.L. received travel support from Micropos Medical and RaySearch Laboratories. The other authors declare no conflict of interest with respect to the contents of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}